Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.42 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL764989 | 0.93 | SLC6A2 (0.67) | SLC6A2SLC6A3SLC6A4AKR1C2FAAH | |
| SCHEMBL8636154 | 0.88 | MEN1 (0.53) | AKR1C2AKR1C1MEN1POLBMAPT | |
| SCHEMBL13719385 | 0.85 | AKR1C2 (0.53) | SLC6A2SLC6A3AKR1C2AKR1C1MAOB | |
| SCHEMBL21782941 | 0.83 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4MAOBMEN1 | |
| SCHEMBL20714984 | 0.83 | SLC6A2 (0.88) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL9771456 | 0.82 | PTGS1 (0.52) | AKR1C2AKR1C1MEN1POLBMAPT | |
| SCHEMBL23319649 | 0.81 | MEN1 (0.53) | AKR1C2AKR1C1MEN1POLBMAPT | |
| SCHEMBL13719535 | 0.81 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4MAOBPPARG | |
| SCHEMBL17297763 | 0.81 | TAAR1 (0.62) | MAOBALOX5 | |
| SCHEMBL1131597 | 0.80 | PTGS1 (0.56) | AKR1C2MEN1POLBMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321251-A1 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230321251-A1 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | OSAKA UNIVERSITY (JP) | 2023-10-12 | — | — | US | disclosed |
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230174584-A1 | Antibiotic Compounds | UNIVERSITEIT LEIDEN (NL) | 2023-06-08 | — | — | US | disclosed |
| US-20230174584-A1 | Antibiotic Compounds | UNIVERSITEIT LEIDEN (NL) | 2023-06-08 | — | — | US | disclosed |
| US-20230146239-A1 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230146239-A1 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021217047-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-10-28 | — | — | WO | disclosed |
| WO-2021060980-A1 | ANTIBIOTIC COMPOUNDS | UNIVERSITEIT LEIDEN (NL) | 2021-04-01 | — | — | WO | disclosed |
| US-10577395-B2 | N-(hydrophobe-substituted) vancosaminyl [Ψ-[C(=NH) NH] Tpg4] vancomycin and [Ψ-[CH2NH]Tpg4] vancomycin | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-03-03 | — | — | US | disclosed |
| US-20150079618-A1 | METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2015-03-19 | — | — | US | disclosed |
| US-8471024-B2 | Tetrahydrofuropyridones | MERCK SHARP & DOHME, CORP. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20110136759-A1 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-09 | — | — | US | disclosed |
| US-20100331358-A1 | TETRAHYDROFUROPYRIDONES | MERCK SHARP & DOHME LLC | 2010-12-30 | — | — | US | disclosed |
| WO-2009046314-A2 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-04-09 | — | — | WO | disclosed |
| WO-2007121124-A2 | HCV INHIBITORS COMPRISING BETA AMINO ACIDS AND THEIR USES | NOVARTIS AG (CH) | 2007-10-25 | — | — | WO | disclosed |
| US-7265086-B2 | Glycopeptide carboxy-saccharide derivatives | THERAVANCE, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7265086-B2 | Glycopeptide carboxy-saccharide derivatives | THERAVANCE, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20070042942-A1 | Glycopeptide carboxy-saccharide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-02-22 | — | — | US | disclosed |
| US-20070042942-A1 | Glycopeptide carboxy-saccharide derivatives | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230321251-A1 | LIPOSOME FORMULATION CONTAINING ANTIBACTERIAL AGENT | LIPA, LIPG, LIPC | SLC6A2 1751/4885SLC6A3 2592/4885SLC6A4 3129/4885 |
| US-20110136759-A1 | MOENOMYCIN ANALOGS, METHODS OF SYNTHESIS, AND USES THEREOF | MSN, MGAM, NISCH | SLC6A2 3988/4885SLC6A3 4101/4885SLC6A4 4388/4885 |
| US-20100331358-A1 | TETRAHYDROFUROPYRIDONES | HIF1AN, EGLN3, HIF1A | SLC6A2 3357/4885SLC6A3 2704/4885SLC6A4 1601/4885 |
| US-10577395-B2 | N-(hydrophobe-substituted) vancosaminyl [Ψ-[C(=NH) NH] Tpg4] vancomycin and [Ψ-[CH2NH]Tpg4] vancomycin | VNN1, VAC14, RPN1 | SLC6A2 720/4885SLC6A3 546/4885SLC6A4 267/4885 |
| US-20070042942-A1 | Glycopeptide carboxy-saccharide derivatives | CSGALNACT1, FUT6, OGT | SLC6A2 3558/4885SLC6A3 2868/4885SLC6A4 2879/4885 |
| US-20230203096-A1 | EPHA4 TARGETING COMPOUNDS AND METHODS OF USE THEREOF | EPHA4, EPHA1, EPHA5 | SLC6A2 1238/4885SLC6A3 1226/4885SLC6A4 481/4885 |
| US-20230146239-A1 | GUANIDINE-MODIFIED C-TERMINUS VANCOMYCIN COMPOUNDS, COMPOSITIONS AND METHODS | RNMT, RNGTT, CAPG | SLC6A2 4671/4885SLC6A3 4299/4885SLC6A4 3961/4885 |
| US-20230174584-A1 | Antibiotic Compounds | RPN1, STT3B, RPN2 | SLC6A2 2334/4885SLC6A3 1860/4885SLC6A4 2763/4885 |
| US-20150079618-A1 | METHODS AND COMPOUNDS FOR IDENTIFYING GLYCOSYLTRANSFERASE INHIBITORS | MAGT1, GALNT1, NMT1 | SLC6A2 1794/4885SLC6A3 1928/4885SLC6A4 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.